Research & Literature

Carpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis.

Nakagawa M, Sekijima Y, Yazaki M, et al.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2016; (23(1)):58-63 doi:10.3109/13506129.2015.1135792.

Comparison of the standard and speckle tracking echocardiographic features of wild-type and mutated transthyretin cardiac amyloidoses.

Minamisawa M, Koyama J, Sekijima Y, et al.

European heart journal. Cardiovascular Imaging 2016; (17(4)):402-10 doi:10.1093/ehjci/jew003.

Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis.

Gillmore JD, Maurer MS, Falk RH, et al.

Circulation 2016; (133(24)):2404-12 doi:10.1161/CIRCULATIONAHA.116.021612.

Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System.

Grogan M, Scott CG, Kyle RA, et al.

Journal of the American College of Cardiology 2016; (68(10)):1014-20.

Association Between Ruptured Distal Biceps Tendon and Wild-Type Transthyretin Cardiac Amyloidosis.

Geller HI, Singh A, Alexander KM, et al.

JAMA 2017; (318(10)):962-963 doi:10.1001/jama.2017.9236.

A new staging system for cardiac transthyretin amyloidosis.

Gillmore JD, Damy T, Fontana M, et al.

European heart journal 2018; (39(30)):2799-2806 doi:10.1093/eurheartj/ehx589.

Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience.

Mints YY, Doros G, Berk JL, et al.

ESC heart failure 2018; (5(5)):772-779 doi:10.1002/ehf2.12308.

Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.

Maurer MS, Schwartz JH, Gundapaneni B, et al.

The New England journal of medicine 2018; (379(11)):1007-1016 doi:10.1056/NEJMoa1805689.

Hereditary transthyretin-related amyloidosis.

Finsterer J, Iglseder S, Wanschitz J, et al.

Acta neurologica Scandinavica 2019; (139(2)):92-105 doi:10.1111/ane.13035.

Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy.

Judge DP, Heitner SB, Falk RH, et al.

Journal of the American College of Cardiology 2019; (74(3)):285-295 doi:10.1016/j.jacc.2019.03.012.

Cardiac amyloidosis: An underdiagnosed/underappreciated disease.

Manolis AS, Manolis AA, Manolis TA, Melita H

European journal of internal medicine 2019; (67()):1-13 doi:10.1016/j.ejim.2019.07.022.

Amyloidosis: diagnosis and new therapies for a misunderstood and misdiagnosed disease.

Thomas VE, Smith J, Benson MD, Dasgupta NR

Neurodegenerative disease management 2019; (9(6)):289-299 doi:10.2217/nmt-2019-0020.

Advantages and Emerging Problems of Novel Treatments for Transthyretin Cardiac Amyloidosis.

Okumura T, Murohara T

Circulation journal : official journal of the Japanese Circulation Society 2019; (84(1)):9-10 doi:10.1253/circj.CJ-19-1044.

Biomarkers and Prediction of Prognosis in Transthyretin-Related Cardiac Amyloidosis: Direct Comparison of Two Staging Systems.

Cappelli F, Martone R, Gabriele M, et al.

The Canadian journal of cardiology 2020; (36(3)):424-431 doi:10.1016/j.cjca.2019.12.020.

Diagnosis of Transthyretin Amyloid Cardiomyopathy.

Hafeez AS, Bavry AA

Cardiology and therapy 2020; (9(1)):85-95 doi:10.1007/s40119-020-00169-4.

Peripheral neuropathy symptoms in wild type transthyretin amyloidosis.

Wajnsztajn Yungher F, Kim A, Boehme A, et al.

Journal of the peripheral nervous system : JPNS 2020; (25(3)):265-272 doi:10.1111/jns.12403.

Quantification of amyloid deposition using bone scan agents.

Kudo T, Imakhanova A

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 2022; (29(2)):515-518 doi:10.1007/s12350-020-02340-9.

Transthyretin amyloid deposits in lumbar spinal stenosis and assessment of signs of systemic amyloidosis.

Eldhagen P, Berg S, Lund LH, et al.

Journal of internal medicine 2021; (289(6)):895-905 doi:10.1111/joim.13222.

Utility of Neuropathy Screening for Wild-Type Transthyretin Amyloidosis Patients.

Russell A, Hahn C, Chhibber S, et al.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2021; (48(5)):607-615 doi:10.1017/cjn.2020.271.

Updates in Cardiac Amyloidosis Diagnosis and Treatment.

Stern LK, Kittleson MM

Current oncology reports 2021; (23(4)):47 doi:10.1007/s11912-021-01028-8.

Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathy.

Law S, Petrie A, Chacko L, et al.

Heart (British Cardiac Society) 2022; (108(6)):474-478 doi:10.1136/heartjnl-2021-319063.

False-positive bone scintigraphy denoting transthyretin amyloid in elderly hypertrophic cardiomyopathy.

Chimenti C, Alfarano M, Maestrini V, et al.

ESC heart failure 2021; (8(4)):3387-3391 doi:10.1002/ehf2.13339.

Lumbar ligamentum flavum burden: Evaluating the role of ATTRwt amyloid deposition in ligamentum flavum thickness at all lumbar levels.

George KM, Hernandez NS, Breton J, et al.

Clinical neurology and neurosurgery 2021; (206()):106708 doi:10.1016/j.clineuro.2021.106708.

Multidisciplinary Approaches for Transthyretin Amyloidosis.

Koike H, Okumura T, Murohara T, Katsuno M

Cardiology and therapy 2021; (10(2)):289-311 doi:10.1007/s40119-021-00222-w.

99mTc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis.

Quarta CC, Zheng J, Hutt D, et al.

European heart journal. Cardiovascular Imaging 2021; (22(11)):1304-1311 doi:10.1093/ehjci/jeab095.

Association between spinal stenosis and wild-type ATTR amyloidosis.

Godara A, Riesenburger RI, Zhang DX, et al.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2021; (28(4)):226-233 doi:10.1080/13506129.2021.1950681.

A Middle-Aged Man Presenting With Progressive Heart Failure, Myopathy, and Monoclonal Gammopathy of Uncertain Significance.

Broch K, Popperud T, Gude E, et al.

JACC. Case reports 2020; (2(5)):785-789 doi:10.1016/j.jaccas.2020.02.024.

In Vitro and In Vivo Effects of SerpinA1 on the Modulation of Transthyretin Proteolysis.

Bezerra F, Niemietz C, Schmidt HHJ, et al.

International journal of molecular sciences 2021; (22(17)) doi:10.3390/ijms22179488.

Screening for hereditary transthyretin amyloidosis in Bulgaria.

Nakov R, Nakov V, Gospodinova M, et al.

Medicine and pharmacy reports 2021; (94(Suppl No 1)):S8-S10 doi:10.15386/mpr-2218.

Clinical and apparative investigation of large and small nerve fiber impairment in mixed cohort of ATTR-amyloidosis: impact on patient management and new insights in wild-type.

Papagianni A, Ihne S, Zeller D, et al.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2022; (29(1)):14-22 doi:10.1080/13506129.2021.1976751.

Glavonoid, a possible supplement for prevention of ATTR amyloidosis.

Matsushita H, Isoguchi A, Okada M, et al.

Heliyon 2021; (7(10)):e08101 doi:10.1016/j.heliyon.2021.e08101.

ATTR Amyloidosis: Current and Emerging Management Strategies: JACC: CardioOncology State-of-the-Art Review.

Griffin JM, Rosenthal JL, Grodin JL, et al.

JACC. CardioOncology 2021; (3(4)):488-505 doi:10.1016/j.jaccao.2021.06.006.

Current and Emerging Therapies for Hereditary Transthyretin Amyloidosis: Strides Towards a Brighter Future.

Obici L, Mussinelli R

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2021; (18(4)):2286-2302 doi:10.1007/s13311-021-01154-y.

Amyloid Cardiopathy and Aortic Stenosis.

Gherasim L

Maedica 2021; (16(3)):473-481 doi:10.26574/maedica.2020.16.3.473.

Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis.

Kleefeld F, Scherret E, Knebel F, et al.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2022; (29(2)):92-101 doi:10.1080/13506129.2021.2014448.

Step-by-step typing for the accurate diagnosis of concurrent light chain and transthyretin cardiac amyloidosis.

Moriyama H, Kitakata H, Endo J, et al.

ESC heart failure 2022; (9(2)):1474-1477 doi:10.1002/ehf2.13773.

Transthyretin: Its function and amyloid formation.

Ueda M

Neurochemistry international 2022; (155()):105313 doi:10.1016/j.neuint.2022.105313.

Prognostic value of right ventricular global longitudinal strain in transthyretin amyloid cardiomyopathy.

Usuku H, Takashio S, Yamamoto E, et al.

Journal of cardiology 2022; (80(1)):56-63 doi:10.1016/j.jjcc.2022.02.010.

Treatment of Transthyretin Amyloid Cardiomyopathy: The Current Options, the Future, and the Challenges.

Tschöpe C, Elsanhoury A

Journal of clinical medicine 2022; (11(8)) doi:10.3390/jcm11082148.

Characteristics and natural history of early-stage cardiac transthyretin amyloidosis.

Law S, Bezard M, Petrie A, et al.

European heart journal 2022; (43(27)):2622-2632 doi:10.1093/eurheartj/ehac259.

A Case of Wild-type Cardiac Transthyretin Amyloidosis Diagnosed by Non-invasive Methods.

Lizarazo Ortega DA, Valderrama BP, González-Robledo G, Trujillo PB

Current medical imaging 2023; (19(4)):402-406 doi:10.2174/1573405618666220610091446.

Identification of wild-type transthyretin cardiac amyloidosis in patients with carpal tunnel syndrome surgery (CACTuS).

Ladefoged B, Clemmensen T, Dybro A, et al.

ESC heart failure 2023; (10(1)):234-244 doi:10.1002/ehf2.14173.

Skeletal muscle 99mTechnetium-pyrophosphate scan: More questions than answers.

Pinto MV, Liewluck T

Muscle & nerve 2023; (67(2)):98-100 doi:10.1002/mus.27754.

Wild type cardiac amyloidosis: is it time to order a nuclear technetium pyrophosphate SPECT imaging study?

Shen CP, Vanichsarn CT, Pandey AC, et al.

The international journal of cardiovascular imaging 2023; (39(1)):201-208 doi:10.1007/s10554-022-02692-y.

Case Report and Literature Review of Cardiac Amyloidosis: A Not-So-Rare Cause of Heart Failure.

Baptista P, Moura de Azevedo S, Alexandre A, Dias-Frias A

Cureus 2023; (15(1)):e33364 doi:10.7759/cureus.33364.

Health-related quality of life among transthyretin amyloid cardiomyopathy patients.

Eldhagen P, Lehtonen J, Gude E, et al.

ESC heart failure 2023; (10(3)):1871-1882 doi:10.1002/ehf2.14350.

Amyloidosis of the Heart: A Comprehensive Review.

Imdad U

Cureus 2023; (15(2)):e35264 doi:10.7759/cureus.35264.

Clinical characteristics and prognostic implications of orthopedic ligament disorders in patients with wild-type transthyretin amyloidosis cardiomyopathy.

Klarskov VR, Ladefoged BT, Pedersen ALD, et al.

Journal of cardiology 2023; (82(2)):122-127 doi:10.1016/j.jjcc.2023.04.019.

Emerging Role of Scintigraphy Using Bone-Seeking Tracers for Diagnosis of Cardiac Amyloidosis: AJR Expert Panel Narrative Review.

Slart RHJA, Chen W, Tubben A, et al.

AJR. American journal of roentgenology 2024; (222(1)):e2329347 doi:10.2214/AJR.23.29347.

The Emerging Significance of Amyloid Deposits in the Ligamentum Flavum of Spinal Stenosis Patients: A Review.

Wang AY, Patel J, Kanter M, et al.

World neurosurgery 2023; (177()):88-97 doi:10.1016/j.wneu.2023.06.037.

A simple ATTR-CM score to identify transthyretin amyloid cardiomyopathy burden in HFpEF patients.

Ye M, Liu X, Gu Z, et al.

European journal of clinical investigation 2023; (53(11)):e14045 doi:10.1111/eci.14045.

Characteristics of Carpal Tunnel Syndrome in Wild-Type Transthyretin Amyloidosis.

Russell A, Khayambashi S, Fine NM, et al.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2024; (51(4)):482-486 doi:10.1017/cjn.2023.268.

Insights Regarding the Article "Exploring Transthyretin Amyloid Cardiomyopathy: A Comprehensive Review of the Disease and Upcoming Treatments".

Sandeep B, Ma C, Chen J, Xiao Z

Current problems in cardiology 2024; (49(1 Pt B)):102100 doi:10.1016/j.cpcardiol.2023.102100.

Tafamidis in patients with severe heart failure due to transthyretin amyloidosis cardiomyopathy: Improved long-term survival.

Tubben A, Nienhuis HLA, van der Meer P

European journal of heart failure 2023; (25(11)):2065-2066 doi:10.1002/ejhf.3053.

Tafamidis Efficacy Among Octogenarian Patients in the Phase 3 ATTR-ACT and Ongoing Long-Term Extension Study.

Garcia-Pavia P, Sultan MB, Gundapaneni B, et al.

JACC. Heart failure 2024; (12(1)):150-160 doi:10.1016/j.jchf.2023.08.032.

Prevalence of transthyretin amyloidosis in patients undergoing carpal tunnel surgery: a prospective cohort study and risk factor analysis.

Brunet J, Rabarin F, Maugendre E, et al.

The Journal of hand surgery, European volume 2024; (49(8)):1002-1007 doi:10.1177/17531934231218997.

Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy.

Gillmore JD, Judge DP, Cappelli F, et al.

The New England journal of medicine 2024; (390(2)):132-142 doi:10.1056/NEJMoa2305434.

Current barriers and recommendations on the diagnosis of transthyretin amyloid cardiomyopathy: a Delphi study.

Çavuşoğlu Y, Başarıcı İ, Tüfekçioğlu O, et al.

Frontiers in cardiovascular medicine 2024; (11()):1299261 doi:10.3389/fcvm.2024.1299261.

Neuromuscular manifestations of wild type transthyretin amyloidosis: a review and single center's experience.

Živković SA, Lacomis D, Soman P

Frontiers in cardiovascular medicine 2024; (11()):1345608 doi:10.3389/fcvm.2024.1345608.

Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Variant Transthyretin Amyloid Cardiomyopathy.

Streicher N, Amass L, Wang R, et al.

Cardiology and therapy 2024; (13(2)):359-368 doi:10.1007/s40119-024-00362-9.

Cardiac Biomarker Change at 1 Year After Tafamidis Treatment and Clinical Outcomes in Patients With Transthyretin Amyloid Cardiomyopathy.

Kuyama N, Takashio S, Oguni T, et al.

Journal of the American Heart Association 2024; (13(10)):e034518 doi:10.1161/JAHA.124.034518.

Single German centre experience with patient journey and care-relevant needs in amyloidosis: The German AMY-NEEDS research and care program.

Ihne-Schubert SM, Leberzammer M, Weidgans M, et al.

PloS one 2024; (19(5)):e0297182 doi:10.1371/journal.pone.0297182.

Cardiovascular autonomic failure in hereditary transthyretin amyloidosis and TTR carriers is an early and progressive disease marker.

Chiaro G, Stancanelli C, Koay S, et al.

Clinical autonomic research : official journal of the Clinical Autonomic Research Society 2024; (34(3)):341-352 doi:10.1007/s10286-024-01038-z.

The Role of Scintigraphy with Bone Radiotracers in Cardiac Amyloidosis.

Morfino P, Aimo A, Giorgetti A, et al.

Heart failure clinics 2024; (20(3)):307-316 doi:10.1016/j.hfc.2024.03.003.

Tafamidis in the Treatment of ATTR-related Cardiomyopathy: Indications and Grey Zones.

Capovilla TM, Lalario A, Rossi M, et al.

Heart failure clinics 2024; (20(3)):333-341 doi:10.1016/j.hfc.2024.03.007.

Expansion of the National Amyloidosis Centre staging system to detect early mortality in transthyretin cardiac amyloidosis.

Nitsche C, Ioannou A, Patel RK, et al.

European journal of heart failure 2024; (26(9)):2008-2012 doi:10.1002/ejhf.3354.

Response to therapy with tafamidis 61 mg in patients with cardiac transthyretin amyloidosis: real-world experience since approval.

Aus dem Siepen F, Meissner C, Hofmann E, et al.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2024; (31(3)):226-231 doi:10.1080/13506129.2024.2376202.

Age- and Sex-Related Differences in Patients With Wild-Type Transthyretin Amyloidosis: Insights From THAOS.

Mora-Ayestaran N, Dispenzieri A, Kristen AV, et al.

JACC. Advances 2024; (3(8)):101086 doi:10.1016/j.jacadv.2024.101086.

Health-related quality of life is an independent predictor of mortality and hospitalisations in transthyretin amyloid cardiomyopathy: a prospective cohort study.

Poledniczek M, Kronberger C, Willixhofer R, et al.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2024; (33(10)):2743-2753 doi:10.1007/s11136-024-03723-y.

Transthyretin amyloid cardiomyopathy: Literature review and red-flag symptom clusters for each cardiology specialty.

Izumiya Y, Kubo T, Endo J, et al.

ESC heart failure 2025; (12(2)):955-967 doi:10.1002/ehf2.15016.

Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy.

Fontana M, Berk JL, Gillmore JD, et al.

The New England journal of medicine 2025; (392(1)):33-44 doi:10.1056/NEJMoa2409134.

Contextualizing the results of HELIOS-B in the broader landscape of clinical trials for the treatment of transthyretin cardiac amyloidosis.

Girard AA, Sperry BW

Heart failure reviews 2025; (30(1)):69-73 doi:10.1007/s10741-024-10444-4.

Role of biomarkers in early diagnosis and prognosis of cardiac amyloidosis: A systematic review and meta-analysis.

Albulushi A, Buraiki JA, Aly G, et al.

Current problems in cardiology 2025; (50(1)):102883 doi:10.1016/j.cpcardiol.2024.102883.

The journey to diagnosis of wild-type transthyretin-mediated (ATTRwt) amyloidosis: a path with multisystem involvement.

Karam C, Moffit C, Summers C, et al.

Orphanet journal of rare diseases 2024; (19(1)):419 doi:10.1186/s13023-024-03407-3.

From Molecular to Radionuclide and Pharmacological Aspects in Transthyretin Cardiac Amyloidosis.

Stanciu SM, Jurcut R, Dragoi Galrinho R, et al.

International journal of molecular sciences 2024; (26(1)) doi:10.3390/ijms26010146.

Guideline-Directed Medical Therapy for Heart Failure in Transthyretin Amyloid Cardiomyopathy.

Schwarting SK, Bieber T, Davies DR, et al.

Circulation. Heart failure 2025; (18(4)):e011796 doi:10.1161/CIRCHEARTFAILURE.124.011796.

Cardiac amyloidosis after lumbar spinal stenosis surgery - a comprehensive prospective cohort study.

Eldhagen P, Tzortzakakis A, Lund LH, et al.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2025; (32(3)):218-225 doi:10.1080/13506129.2025.2481310.

Early cardiovascular autonomic failure in ATTRv predicts poor prognosis and may respond to disease-modifying therapy.

Sander L, Chiaro G, Abelardo D, et al.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2025; (32(3)):246-254 doi:10.1080/13506129.2025.2494657.

High-Sensitivity Cardiac Troponin I for Risk Stratification in Wild-Type Transthyretin Amyloid Cardiomyopathy.

De Michieli L, Sinigiani G, Guida G, et al.

Circulation. Heart failure 2025; (18(8)):e012816 doi:10.1161/CIRCHEARTFAILURE.125.012816.

Differential Binding Affinities and Kinetics of Transthyretin Stabilizers.

Ji AX, Betz A, Sinha U

Journal of cardiovascular pharmacology 2025; doi:10.1097/FJC.0000000000001726.

Transthyretin Amyloid Cardiomyopathy-2025 Update: Current Diagnostic Approaches and Emerging Therapeutic Options.

Tschöpe C, Elsanhoury A, Kristen AV

Journal of clinical medicine 2025; (14(13)) doi:10.3390/jcm14134785.

Tafamidis: A game changer in transthyretin cardiomyopathy? A systematic review and meta-analysis of safety and efficacy.

Hussain B, Duhan S, Patel B, et al.

Current problems in cardiology 2025; (50(9)):103129 doi:10.1016/j.cpcardiol.2025.103129.

Transthyretin Kinetic Stabilizers for ATTR Amyloidosis: A Narrative Review of Mechanisms and Therapeutic Benefits.

Powers ET, Amass L, Baylor L, et al.

Cardiology and therapy 2025; (14(3)):333-350 doi:10.1007/s40119-025-00423-7.

Transthyretin cardiac amyloidosis: advances and ambiguities.

Danilov A, D'Angelo L, Marsela E, et al.

Heart failure reviews 2025; (30(6)):1341-1352 doi:10.1007/s10741-025-10552-9.

Impact of patisiran on polyneuropathy of hereditary transthyretin amyloidosis in patients with a V122I or T60A variant: a phase IV multicenter study.

Hussain Y, Malhotra S, Sperry BW, et al.

Annals of medicine 2025; (57(1)):2537347 doi:10.1080/07853890.2025.2537347.

Longitudinal Changes in Multiple Cardiac Biomarkers in Transthyretin Amyloidosis Cardiomyopathy Patients Treated Vs Untreated with Tafamidis.

Shahi K, Miller RJH, Dykstra S, et al.

CJC open 2025; (7(9)):1190-1197 doi:10.1016/j.cjco.2025.05.012.

Non-amyloid specific treatment for transthyretin cardiac amyloidosis: a clinical consensus statement of the ESC Heart Failure Association.

Garcia-Pavia P, Gonzalez-Lopez E, Anderson LJ, et al.

European heart journal 2026; (47(1)):22-36 doi:10.1093/eurheartj/ehaf710.

Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance.

, Kittleson MM, Ambardekar AV, et al.

Journal of the American College of Cardiology 2026; (87(5)):549-565 doi:10.1016/j.jacc.2025.09.004.

Polyneuropathy in Wild-Type Transthyretin Amyloidosis.

Sciarrone MA, Vitali F, Guglielmino V, et al.

European journal of neurology 2025; (32(11)):e70374 doi:10.1111/ene.70374.

Trends in diagnostic testing in Medicare patients with wild-type transthyretin amyloid cardiomyopathy.

Witteles RM, Chung H, Dai F, et al.

Frontiers in cardiovascular medicine 2025; (12()):1638380 doi:10.3389/fcvm.2025.1638380.

The impact of large v-waves of pulmonary artery wedge pressure in patients with wild-type transthyretin amyloid cardiomyopathy.

Yamamoto M, Izumiya Y, Takashio S, et al.

Journal of cardiology 2026; (87(3)):221-229 doi:10.1016/j.jjcc.2025.11.008.

Monitoring Disease Progression in Patients With Transthyretin Amyloid Cardiomyopathy.

García-Pavía P, Witteles RM, Damy T, et al.

JACC. Heart failure 2026; (14(1)):102766 doi:10.1016/j.jchf.2025.102766.

Global Longitudinal Strain for Prognostic Staging in Wild-Type Transthyretin Cardiac Amyloidosis.

Debonnaire P, L'Hoyes W, Donal E, et al.

Circulation. Cardiovascular imaging 2026; (19(1)):e018862 doi:10.1161/CIRCIMAGING.125.018862.

Myocardial Amyloid Burden in Transthyretin Amyloidosis.

Sheikh A, Achten A, Aimo A, et al.

Journal of the American College of Cardiology 2026; (87(5)):505-518 doi:10.1016/j.jacc.2025.10.054.

Multimodality Imaging in Cardiac Amyloidosis.

Chaudhari M, Ashwath ML

Journal of clinical medicine 2025; (15(1)) doi:10.3390/jcm15010163.

Diagnostic Journeys and Delays in AL Amyloidosis: Insights From a Cross-Sectional Patient Survey.

Abdallah NH, Hydren JR, Barnes MS, et al.

Clinical lymphoma, myeloma & leukemia 2026; (26(3)):184-190 doi:10.1016/j.clml.2026.01.003.

Tafamidis treatment in transthyretin cardiac amyloidosis: A retrospective cohort analysis of outcomes and associated factors.

Krief J, Aguilhon S, Delbaere Q, et al.

Archives of cardiovascular diseases 2026; doi:10.1016/j.acvd.2025.12.010.

Hidden overlap between heart failure with preserved ejection fraction and transthyretin amyloid cardiomyopathy: Why it matters and how to avoid missing it.

Tanaka H

International journal of cardiology 2026; (450()):134245 doi:10.1016/j.ijcard.2026.134245.

Association Between Occupational Physical Work Exposure and Wild-Type Transthyretin Cardiomyopathy.

Ladefoged BT, Olesen KK, Maeng M, Poulsen SH

JACC. Advances 2026; (5(3)):102619 doi:10.1016/j.jacadv.2026.102619.